Good morning, ladies and gentlemen. I would like to present preliminary results of our ongoing registry regarding a novel directional system. So, these are my disclosures, Dr. Deutsch and myself, consulting agreements with Boston Scientific. As you all know, the plant simulation was very successful in the past with ring-shaped electrodes. However, there are some limitations regarding calculating the field of simulation, shaping the field, and also the volume it is to activate. This was actually the purpose to develop segmented leads to enable the physician to stimulate in a different direction, and we're using a Martin and Perkins source to control, to better control the management of endothelial-responsive Parkinson's disease. Basically, the results were evaluated in the frame of a registry. We want to include up to 1,000 subjects. Meanwhile, 25% are done. However, there are already interesting results I would like to present. Now, this is not just improving the UPDRs, but predominantly the quality of life items as PDQ39, clinical over-expression, Schwab implant, and also the Q5D, and obviously also adverse events were reported. Patient characters are interesting. As you can see, patients for ongoing brain stimulation become younger and younger. So in the past, we had not only elderly patients, but also more affected patients. As you can see, UPDRs is not as high, so meaning that the patients are still in the earlier stage of their disease. However, we were able to improve, so patients were less affected than others cohorts. So we were able to show that we could significantly improve the quality of life. And here, PDQ39, it was even better after one year with those patients in care. This is also true for the SDS-UPDRs with an older function, which is significantly improved from 44 to 30 after one year. My favorite slide is this one, reflecting the advantages of deep brain stimulation, showing that not only the physician and the presenter are happy with the deep brain stimulation, but also the caregiver and the subject. And this is really interesting that we have now over 90% rate of overall satisfaction with the therapy. There were no really anticipated adverse events, no mechanical failures, which is interesting. And so we were resulting in a couple of serious adverse events. However, nothing really limits the results of our therapy. So in the end of the day, we were able to show the significant improvement in quality of life and also the truth for demonstrating improving the motor function. And over 90% of such updates were happy with the improvement of Parkinson's disease symptoms. The overall safety is acceptable, is comparable to those which was published before. The registry, as I mentioned, is still ongoing and we are looking forward to see it fulfilled in one or two years. Thank you very much for your attention.

deep brain stimulation

Parkinson's disease

directional system

registry

improved quality of life